Cervical Cancer Research Reagents

Cervical cancer is the fourth most common cancer in women worldwide, with virtually all cases caused by persistent high-risk HPV infection (predominantly types 16 and 18). HPV oncoproteins E6 (degrading p53) and E7 (inactivating RB) are the essential drivers of malignant transformation. Pembrolizumab (anti-PD-1) in PD-L1 CPS ≥1 tumors and tisotumab vedotin (anti-tissue factor ADC) have transformed treatment for recurrent/metastatic disease.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Cervical Cancer Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in cervical cancer. HPV E6/E7-driven oncogenesis, PD-1/PD-L1 immune checkpoint, and tissue factor-targeted ADC therapy. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key cervical cancer research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

p16INK4a (CDKN2A) — p16 overexpression is a direct consequence of HPV E7-mediated RB inactivation and serves as the standard IHC surrogate marker for high-risk HPV infection. Anti-p16 antibodies enable diagnostic confirmation, CIN grading, and research into HPV-driven cell cycle deregulation.
→ Browse p16 antibodies

PD-L1 (CD274) — PD-L1 CPS ≥1 selects cervical cancer patients for pembrolizumab therapy. Anti-PD-L1 antibodies support CPS validation, tumor microenvironment immune profiling, and checkpoint combination therapy research in HPV-driven cancers where chronic viral infection shapes the immune response.
→ Browse PD-L1 antibodies & proteins

Tissue Factor (TF, F3, CD142) — Tissue factor is overexpressed on cervical cancer cells and serves as the target for tisotumab vedotin (anti-TF ADC). Anti-tissue factor antibodies enable IHC expression profiling, ADC internalization and trafficking studies, and coagulation pathway research in the tumor microenvironment.
→ Browse Tissue Factor antibodies & proteins

References

1. Colombo N, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. DOI

2. Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Lancet Oncol. 2021;22(5):609-619. DOI

3. Tewari KS, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743. DOI

4. The Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. DOI